Table 1.
Run | Factors
|
Observed results
|
|||
---|---|---|---|---|---|
X1 (mg/mL) | X2 | X3 (mg) | EE (%) | DL (%) | |
1 | 12 | 8 | 7 | 73.33 | 14.00 |
2 | 12 | 16 | 6 | 68.97 | 13.60 |
3 | 12 | 8 | 5 | 79.80 | 12.10 |
4 | 16 | 16 | 4 | 75.00 | 10.14 |
5 | 16 | 8 | 7 | 63.40 | 13.62 |
6 | 16 | 16 | 6 | 70.73 | 11.49 |
7 | 20 | 4 | 5 | 86.72 | 10.38 |
8 | 20 | 12 | 4 | 66.19 | 8.61 |
9 | 20 | 4 | 7 | 84.18 | 17.41 |
10 | 24 | 12 | 6 | 69.79 | 10.42 |
11 | 24 | 4 | 5 | 85.22 | 10.48 |
12 | 24 | 12 | 4 | 76.01 | 7.10 |
Notes: X1, the PLGA concentration; X2, the volume ratio of the aqueous phase to the oil phase; X3, the AP feeding amount.
Abbreviations: AP, acetylpuerarin; DL, drug loading; EE, encapsulation efficiency; PLGA, poly(lactide-co-glycolide); UD, uniform design.